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Identity 
Other names: Mediastinal carcinoma with 
chromosome translocation t(15;19); Midline carcinoma 
of children and young adults with NUT rearrangement; 
Midline carcinoma with t(15;19); Poorly differentiated 
carcinoma with t(15;19); Poorly differentiated thymic 
carcinoma; t(15;19) positive tumor. 
Clinics and pathology 
Disease  
Carcinoma with t(15;19) translocation. 
Phenotype stem cell origin 
It has been suggested that tumor cells derive from early 
epithelial progenitor cells. 
Embryonic origin 
The majority of the cases presumably derive from 
various (midline) epithelial surfaces. One tumor, 
localized to the iliac bone and staining negative for 
epithelial, endothelial, germ cell and neuroendocrine 
markers has been reported, suggesting that the tumor 




A total of 13 cases have been reported to date. All 
tumors occurred in children or young adults with a 
median age of 15 years of age (range 3-35). There seem 
to be no sex predilection (8 males, 5 females). 
Clinics 
The growth pattern is typically aggressive and locally 
invasive. Metastatic growth is common in particular in 
bone, but also in lymph nodes and lungs. 
Cytology 
Focal reactivity with pan-cytokeratin markers. Negative 
for CD30, CD45, PLAP, HMB45, S100 and 
neuroendocrine markers. 
Pathology 
The tumor cells are typically undifferentiated, of 
intermediate size and the mitotic index is high. 
Treatment 
Intensive combined chemotherapy and occasionally 
radiotherapy. 
Prognosis 
Extremely poor. Among the cases reported so far, the 
median survival time was 18 weeks (range 6-67). 
It has been suggested that a critical prognostic 
difference exists between BRD4-NUT/t(15;19) positive 
tumors and tumors where NUT is rearranged but fused 
to an as yet unknown partner. 
Cytogenetics 
Cytogenetics morphological 
The characteristic t(15;19) has been observed in all 
reported cases. The reported breakpoints on 
chromosome 15 have varied (15q11-q15). The 
breakpoints on chromosome 19 clustered to 19p13 in 
the majority of the cases. In one case the breakpoint 
was interpreted as 19q13. 
Cytogenetics molecular 
Various FISH protocols for the detection of 15q and 
19p rearrangements, strongly indicating the presence of 
a t(15;19), have been reported. The material used has 
been paraffin-embedded sections of tumor biopsy or 
metaphase spreads of cultured tumor tissue. 
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Probes 
Probes for NUT: RP11-194H7 covering the gene or 
BAC 87M17 and YAC 766E7 flanking the gene. 
Probes for BRD4: RP11-637P24 covering the gene or 
BACs 1H8+64O3 and BACs 412E10+3D4 flanking the 
gene. 
Additional anomalies 
The t(15;19) is typically seen as the sole change. In one 
case a variant t(11;15;19) was reported. 
Variants 
t(15;?)(q14;?) leading to rearrangement and fusion of 
NUT to an unknown partner gene. 
Genes involved and Proteins 
NUT (nuclear protein in testis) 
Location: 15q14 (position 32425358-32437221 on the 
chromosome 15 genomic sequence according to the 
UCSC database; assembly of May 2004) 
DNA/RNA 
The gene consists of 7 exons that span approximately 
12 kb of genomic DNA in the centromere-to-telomere 
orientation. The translation initiation codon and the 
stop codon are predicted to exon 1 and exon 7, 
respectively. The corresponding wildtype mRNA 
transcript is 3.6 kb. 
Protein 
The open reading frame is predicted to encode a 1127 
amino acid protein with an estimated molecular weight 
of 120 kDa. The protein is nuclear and Northern blot 
analysis has indicated that the normal expression of the 
NUT gene is highly restricted to the testis. 
BRD4 (bromodomain containing 4) 
Location: 19p13 (position 15252262-15209302 on the 
chromosome 19 genomic sequence according to the 
UCSC database; assembly of May 2004). 
DNA/RNA 
The gene consists of 20 exons that span approximately 
43 kb of genomic DNA in the centromere-to-telomere 
orientation. The translation initiation codon and stop 
codon are located to exon 2 and exon 20, respectively. 
Two isoforms of BRD4 have been reported. The BRD4 
long isoform encodes a 6.0 kb mRNA that corresponds 
to the full length transcript. The BRD4 short isoform 
encodes a 4.4 kb mRNA that corresponds to an 
alternative splicing variant lacking exons 12-20. 
Protein 
The open reading frame encodes a 1362 amino acid 
protein with a molecular weight of 200 kDa. The 
protein is nuclear and Northern blot analysis has shown 
an ubiquitous normal expression of both BRD4 
isoforms. 
 




The t(15;19)(q14;p13) results in a BRD4-NUT 
chimeric gene where exon 10 of BRD4 is fused to exon 
2 of NUT. 
Detection protocole 
The hybrid gene can be visualized by FISH using gene 
specific probes or by RT-PCR. 
Fusion protein 
Description 
The BRD4-NUT fusion protein is composed of the N-
terminal of BRD4 (amino acids 1-720 out of 1372) and 
almost the entire protein sequence of NUT (amino 
acids 6-1127). The N-terminal of BRD4 includes 
bromodomains 1 and 2 and other, less well 
characterized functional domains. 
Oncogenesis 
It has been suggested that the oncogenic effect of the 
NUT-BRD4 fusion is caused not only by the abnormal 
regulation of NUT by BRD4 promotor elements but 
also by the consequent ectopic expression of NUT in 
non-germinal tissues. 
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